NASDAQ:VRNA

Verona Pharma Stock Forecast, Price & News

$8.20
-0.02 (-0.24 %)
(As of 04/14/2021 12:00 AM ET)
Add
Compare
Today's Range
$8.06
Now: $8.20
$8.69
50-Day Range
$7.51
MA: $8.64
$9.30
52-Week Range
$3.70
Now: $8.20
$15.71
Volume43,115 shs
Average Volume127,376 shs
Market Capitalization$475.07 million
P/E RatioN/A
Dividend YieldN/A
Beta0.4
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. Its product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 2 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. The company is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. It also focuses on developing ensifentrine for the treatment of COVID-19. Verona Pharma plc was founded in 2005 and is headquartered in London, the United Kingdom.
Verona Pharma logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:VRNA
CUSIPN/A
Phone44-20-3283-4200
Employees25
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$3.28 per share

Profitability

Net Income$-40,780,000.00

Miscellaneous

Market Cap$475.07 million
Next Earnings Date4/29/2021 (Estimated)
OptionableNot Optionable

Headlines

Revisiting Verona Pharmaceuticals
March 2, 2021 |  seekingalpha.com
News for Verona Pharma PLC Registered Shs
December 24, 2020 |  markets.businessinsider.com
Is VRNA A Good Stock To Buy Now?
December 11, 2020 |  finance.yahoo.com
25 Best U.S. Cities to Live With Asthma
November 25, 2020 |  finance.yahoo.com
Verona Pharma EPS beats by $0.15
October 30, 2020 |  seekingalpha.com
Verona Pharma Plcto Host Earnings Call
October 29, 2020 |  finance.yahoo.com
Verona Pharma plc (I9S1.SG)
October 11, 2020 |  in.finance.yahoo.com
See More Headlines

MarketRank

Overall MarketRank

1.69 out of 5 stars

Medical Sector

282nd out of 2,019 stocks

Pharmaceutical Preparations Industry

122nd out of 772 stocks

Analyst Opinion: 3.5Community Rank: 3.5Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
$8.20
-0.02 (-0.24 %)
(As of 04/14/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive VRNA News and Ratings via Email

Sign-up to receive the latest news and ratings for VRNA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Verona Pharma (NASDAQ:VRNA) Frequently Asked Questions

Is Verona Pharma a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Verona Pharma in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Verona Pharma stock.
View analyst ratings for Verona Pharma
or view top-rated stocks.

What stocks does MarketBeat like better than Verona Pharma?

Wall Street analysts have given Verona Pharma a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Verona Pharma wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Verona Pharma?

Verona Pharma saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 98,100 shares, an increase of 104.8% from the February 28th total of 47,900 shares. Based on an average daily volume of 126,100 shares, the days-to-cover ratio is presently 0.8 days.
View Verona Pharma's Short Interest
.

When is Verona Pharma's next earnings date?

Verona Pharma is scheduled to release its next quarterly earnings announcement on Thursday, April 29th 2021.
View our earnings forecast for Verona Pharma
.

How were Verona Pharma's earnings last quarter?

Verona Pharma plc (NASDAQ:VRNA) posted its quarterly earnings data on Thursday, February, 25th. The company reported ($0.53) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.34) by $0.19.
View Verona Pharma's earnings history
.

How has Verona Pharma's stock price been impacted by Coronavirus?

Verona Pharma's stock was trading at $4.84 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, VRNA shares have increased by 69.4% and is now trading at $8.20.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for VRNA?

3 brokers have issued 1-year target prices for Verona Pharma's stock. Their forecasts range from $17.00 to $23.00. On average, they expect Verona Pharma's stock price to reach $19.00 in the next twelve months. This suggests a possible upside of 131.7% from the stock's current price.
View analysts' price targets for Verona Pharma
or view top-rated stocks among Wall Street analysts.

Who are Verona Pharma's key executives?

Verona Pharma's management team includes the following people:
  • Dr. David S. Zaccardelli, Pres, CEO & Exec. Director (Age 56, Pay $701.63k)
  • Mr. Mark W. Hahn, Chief Financial Officer (Age 58, Pay $560.07k)
  • Dr. Kathleen A. Rickard, Chief Medical Officer (Age 63, Pay $722.76k)
  • Ms. Claire Louise Poll L.C.S.W., B.A., B Juris, LLB, ASIA, Gen. Counsel (Age 54)
  • Ms. Victoria Stewart, Director of Communications
  • Dr. Peter Spargo, Sr. VP of Chemistry Manufacturing & Controls (Age 59)
  • Ms. Nina Church, Exec. Director of Global Clinical Devel.
  • Mr. Benjamin Harber, Company Sec.
  • Mr. Christopher Martin, VP of Commercial

Who are some of Verona Pharma's key competitors?

What other stocks do shareholders of Verona Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Verona Pharma investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Trevena (TRVN), Pfizer (PFE), Citius Pharmaceuticals (CTXR), electroCore (ECOR), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), VBI Vaccines (VBIV) and Vaxart (VXRT).

When did Verona Pharma IPO?

(VRNA) raised $61 million in an initial public offering on Thursday, April 27th 2017. The company issued 4,500,000 shares at $13.49 per share. Jefferies and Stifel acted as the underwriters for the IPO and Wedbush PacGrow and SunTrust Robinson Humphrey were co-managers.

What is Verona Pharma's stock symbol?

Verona Pharma trades on the NASDAQ under the ticker symbol "VRNA."

How do I buy shares of Verona Pharma?

Shares of VRNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Verona Pharma's stock price today?

One share of VRNA stock can currently be purchased for approximately $8.20.

How much money does Verona Pharma make?

Verona Pharma has a market capitalization of $475.07 million. The company earns $-40,780,000.00 in net income (profit) each year or ($3.10) on an earnings per share basis.

How many employees does Verona Pharma have?

Verona Pharma employs 25 workers across the globe.

What is Verona Pharma's official website?

The official website for Verona Pharma is www.veronapharma.com.

Where are Verona Pharma's headquarters?

Verona Pharma is headquartered at 3 MORE LONDON RIVERSIDE, LONDON X0, SE1 2RE.

How can I contact Verona Pharma?

Verona Pharma's mailing address is 3 MORE LONDON RIVERSIDE, LONDON X0, SE1 2RE. The company can be reached via phone at 44-20-3283-4200 or via email at [email protected]


This page was last updated on 4/15/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.